429 related articles for article (PubMed ID: 26997349)
1. Structural basis for germline antibody recognition of HIV-1 immunogens.
Scharf L; West AP; Sievers SA; Chen C; Jiang S; Gao H; Gray MD; McGuire AT; Scheid JF; Nussenzweig MC; Stamatatos L; Bjorkman PJ
Elife; 2016 Mar; 5():. PubMed ID: 26997349
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
[TBL] [Abstract][Full Text] [Related]
3. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.
Gristick HB; von Boehmer L; West AP; Schamber M; Gazumyan A; Golijanin J; Seaman MS; Fätkenheuer G; Klein F; Nussenzweig MC; Bjorkman PJ
Nat Struct Mol Biol; 2016 Oct; 23(10):906-915. PubMed ID: 27617431
[TBL] [Abstract][Full Text] [Related]
4. Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core.
Borst AJ; Weidle CE; Gray MD; Frenz B; Snijder J; Joyce MG; Georgiev IS; Stewart-Jones GB; Kwong PD; McGuire AT; DiMaio F; Stamatatos L; Pancera M; Veesler D
Elife; 2018 Nov; 7():. PubMed ID: 30403372
[TBL] [Abstract][Full Text] [Related]
5. Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies.
Kesavardhana S; Das R; Citron M; Datta R; Ecto L; Srilatha NS; DiStefano D; Swoyer R; Joyce JG; Dutta S; LaBranche CC; Montefiori DC; Flynn JA; Varadarajan R
J Biol Chem; 2017 Jan; 292(1):278-291. PubMed ID: 27879316
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.
Scharf L; West AP; Gao H; Lee T; Scheid JF; Nussenzweig MC; Bjorkman PJ; Diskin R
Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6049-54. PubMed ID: 23524883
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
[TBL] [Abstract][Full Text] [Related]
8. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
9. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
[TBL] [Abstract][Full Text] [Related]
10. Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.
Joyce MG; Kanekiyo M; Xu L; Biertümpfel C; Boyington JC; Moquin S; Shi W; Wu X; Yang Y; Yang ZY; Zhang B; Zheng A; Zhou T; Zhu J; Mascola JR; Kwong PD; Nabel GJ
J Virol; 2013 Feb; 87(4):2294-306. PubMed ID: 23236069
[TBL] [Abstract][Full Text] [Related]
11. Rational HIV immunogen design to target specific germline B cell receptors.
Jardine J; Julien JP; Menis S; Ota T; Kalyuzhniy O; McGuire A; Sok D; Huang PS; MacPherson S; Jones M; Nieusma T; Mathison J; Baker D; Ward AB; Burton DR; Stamatatos L; Nemazee D; Wilson IA; Schief WR
Science; 2013 May; 340(6133):711-6. PubMed ID: 23539181
[TBL] [Abstract][Full Text] [Related]
12. Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.
Rathore U; Saha P; Kesavardhana S; Kumar AA; Datta R; Devanarayanan S; Das R; Mascola JR; Varadarajan R
J Biol Chem; 2017 Jun; 292(24):10197-10219. PubMed ID: 28446609
[TBL] [Abstract][Full Text] [Related]
13. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
Crooks ET; Grimley SL; Cully M; Osawa K; Dekkers G; Saunders K; Rämisch S; Menis S; Schief WR; Doria-Rose N; Haynes B; Murrell B; Cale EM; Pegu A; Mascola JR; Vidarsson G; Binley JM
PLoS Pathog; 2018 May; 14(5):e1007024. PubMed ID: 29718999
[TBL] [Abstract][Full Text] [Related]
14. Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope.
Doores KJ; Kong L; Krumm SA; Le KM; Sok D; Laserson U; Garces F; Poignard P; Wilson IA; Burton DR
J Virol; 2015 Jan; 89(2):1105-18. PubMed ID: 25378488
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.
Zhou T; Georgiev I; Wu X; Yang ZY; Dai K; Finzi A; Kwon YD; Scheid JF; Shi W; Xu L; Yang Y; Zhu J; Nussenzweig MC; Sodroski J; Shapiro L; Nabel GJ; Mascola JR; Kwong PD
Science; 2010 Aug; 329(5993):811-7. PubMed ID: 20616231
[TBL] [Abstract][Full Text] [Related]
16. A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
Joshi VR; Claiborne DT; Pack ML; Power KA; Newman RM; Batorsky R; Bean DJ; Goroff MS; Lingwood D; Seaman MS; Rosenberg E; Allen TM
J Virol; 2024 Mar; 98(3):e0172023. PubMed ID: 38412036
[TBL] [Abstract][Full Text] [Related]
17. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.
McGuire AT; Hoot S; Dreyer AM; Lippy A; Stuart A; Cohen KW; Jardine J; Menis S; Scheid JF; West AP; Schief WR; Stamatatos L
J Exp Med; 2013 Apr; 210(4):655-63. PubMed ID: 23530120
[TBL] [Abstract][Full Text] [Related]
18. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
19. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.
Kong L; Lee JH; Doores KJ; Murin CD; Julien JP; McBride R; Liu Y; Marozsan A; Cupo A; Klasse PJ; Hoffenberg S; Caulfield M; King CR; Hua Y; Le KM; Khayat R; Deller MC; Clayton T; Tien H; Feizi T; Sanders RW; Paulson JC; Moore JP; Stanfield RL; Burton DR; Ward AB; Wilson IA
Nat Struct Mol Biol; 2013 Jul; 20(7):796-803. PubMed ID: 23708606
[TBL] [Abstract][Full Text] [Related]
20. Increasing the potency and breadth of an HIV antibody by using structure-based rational design.
Diskin R; Scheid JF; Marcovecchio PM; West AP; Klein F; Gao H; Gnanapragasam PN; Abadir A; Seaman MS; Nussenzweig MC; Bjorkman PJ
Science; 2011 Dec; 334(6060):1289-93. PubMed ID: 22033520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
